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Abstract
Neuroleptic malignant syndrome is a potentiallyfa tal complication ifneuroleptic treatment.
It is characterized fry a variery ifsigns and symptoms associated with autonomic instability, and
hypothalamic and extrapyramidal dysfunction. Since othermedical disordersmay mimic its clinical
presentation, the accurate recognition if this syndrome in the medical setting is often a diagnostic
dilemma. Three medically ill patients with a clinical presentation suggestive if neuroleptic
malignant syndromearepresentedhere. The authors discuss the complexity ifmaking the diagnosis,
and qjfer a briefreview ifthe literature.
Since it was firs t descr ibed in 1960, a pproximat ely 1000 cases of neurolep tic
mali gn ant syndrome (NMS) have been reported in the lit e ra ture (1-2). Althou gh the
precise pathophysiology is not well understood , NMS is widely recognized as a
pot ent ially fa tal com plica t ion of treatmen t wit h neu rol eptic agents. Studies su ggest
that it is related to decreased ce n t ra l dop a minergic act ivity , most com monly precipi-
ta te d by dop amine D2 receptor blockade in the stria tal and hypotha la mic systems
(3) .
Exp erts have not been able to ident ify accurate ly a subpopulat ion at incre ased
risk for developingthe syndrome . However, a ge ne t ic component ofNMS vulne rabil-
ity has been hypothesized , and a rece nt familial case report proposes th at NMS
suscept ibility may be, in part , a heritabl e cha racterist ic (4) . Case reviews su gg est that
r isk fact ors for developing NMS includ e: I) previou s hist ory ofNMS, 2) intramuscul ar
delivery and / or abrup t increase in rate or tot al dosage of neuroleptic agent, 3)
a n tecede n t dop amine agonist or an t icholine rg ic medi ca tion wit hd rawal, 4) concur-
re n t use of other psychotropi c drugs, 5) e tha nol abuse or dep endence, 6) pr e-existing
br ain pathology, 7) concomitan t medical or neu rological illn ess, 8) dehydration, and
9) psychomot or ag itat ion (5-7). Gender ra t io of NMS is approximately 2: 1 mal e:
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fem ale, with a n ave rage age of onse t of 38-40. Risk facto rs for NMS a re sum marized
in T abl e 1.
Diagn osis of NMS re quires differentiation from clinica lly similar syndro mes
including t he se rotonin syndrome (8-9), monamine oxidase inhibitor-induced hyper-
ten sive crisis, mal ign ant hyperth ermia , heat stroke, a nd let ha l ca ta tonia (10-11).
Va riou s m edi cal a nd neurological illn esses may also resemble NMS , th erefore,
di fferential diagn osis of this syndro me in a me dica l se tt ing may be problem atic ( 12).
Inv esti gators have outlined diagn osti c crite ria to ass ist in dist ingu ishing NMS from
othe r clinicall y simila r en t it ies (7, 12). The major crite ria are bas ed on the presen ce of
I ) a uto no mic instability, 2) ex t ra pyramidal dysfun ction , 3) hyperthermia , a nd 4)
clouded consc ious ness . In addit ion, a variety of abnormal labora tory valu es have been
out lined as mi nor cri teria; I) elevated serum creat ine kinase (C K) activity over 1000
U/ liter, 2) white blood cell count (WBC) over 15.0 X 109 E/liter, 3) eleva ted liver
enzymes, 4) myoglobinuria, 5) elec trolyte ab no rmalities, and 6) diffuse slowing on
elec t roe nce phalog ram (13). Diagn osti c cri teria for NMS a re summarized in T abl es 2
a nd 3.
T reat men t for NMS includes prompt recogn it ion of the syndrome, immedi at e
TABLE 1.
Application of Risk Factors for NMS
Case #1 Case # 2 Case # 3
Demographic
Sex M ivl M
Age 67 72 35
Psych ia t r ic Diagnosis MR MR/CS OB S
Neuro leptic R elated
Maxi mu m dose (mg/24 hou rs}' 7 2.5 5
Initiat ed /Increased dose yes no yes
Pot en cy high high high
Route 1M oral ora l
Polyph a rmacy (psychotropics) yes yes no
Medical! Neurological Status
Psych omotor ag itation yes no yes
Co ncurren t illn esses yes yes yes
Pr eexi st ing brain pathology yes yes yes
Alcoh ol/Subst an ce abuse no no no
Dehydration yes no no
Pr eviou s NMS ? ? no
Iron deficien cy anemia/ yes no no
ICase # I received a combina tion of t rifluperazine 10 mg an d haloperidol 14 mg over a period
of48 hours.
2Alt hough controvers ia l, low se rum iron has been re por ted as a pot enti a l ris k factor for NMS
(18) .
Abb reviati ons: 1M; intramuscul ar-MR; mental ret arda tion- CS; chronic schizophre nia-
OB S; organic brain syndrome.
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dis continuation of psychotropic medi cations, and institution of supportive th erapy.
Dopaminergic agonists such as bromocriptine, a mantadine , L-dopa , and ca lcium
channel blockers , such as dantrolene sod ium , have demon st rat ed effectiveness in
resolution of th e symptoms, and reduction in associa te d mor tality ( 14). A mort al ity
rate of 20-30% sec onda ry to com plica t ions (pulmonary, ren al , cardiovascu lar) ha s
been reported in untreated cases (15).
We report three patients who pr esented to th e medi cal service wit h fever, a nd
un explained eleva te d serum CK. Following psychi atric consultation, on e case was
di agn osed with NMS, and the possibility of NMS was ruled out in another. Assess-
ment for NMS in th e third patient was difficult du e to a complex medical pr esenta-
tion.
CASE #1
A 57-year-old man was tr an sferred from a nursin g hom e to U nive rsity Hospitals of
Cl evel and for eva lua t ion and treatment of a r ight lower ex tre m ity fract ure . T he patient 's past
medi cal hist ory was significa nt for gas t roi n tes tina l bleed ing and iro n deficiency an emia. Hi s
psychi a tri c history was rem arkabl e for mental re tardat ion secondary to a febri le illn ess a t age
four. Befor e ad m ission th e patient had been receivin g furosemide 20 mg dai ly, iron sulfa te 300
mg twice dail y. Hi s treat ment a lso included nortript yline 25 mg twic e dai ly a nd trifluperazin e 2
mg twice daily for psychological an d behavior al abno rmalities.
On day three of hospit ali zation , following an ort hopedic procedure, t he patient dem on-
st ra te d incr ea sin g agi ta t ion, and halop eridol in a dosage of2 mg oral or intramuscu lar every 4
hours as need ed , and ben zt ropine were adde d to his ad m ission med ica tions. Over th e next two
days, he received a tot al of 14 mg int ramuscul ar halop erid ol and 2 mg intramuscu lar
trifluperazin e in addition to his st anding regimen . Subse que nt ly, t he pati ent developed motor
TABLE 2.
Application of Keck's Diagnostic Criteria of NMS
Case #1 Case #2 Case # 3
Major Criteria
Hyperthermia (> = 38°C) yes yes yes
Ex trapyramidal Dysfunction ' yes no yes
Aut onomic Dysfunction'' yes no yes
Minor Criterio''
C loude d Co nsc ious ness yes no yes
Se rum C K > 1000 U / lite r yes yes yes
WBC > 15.0 X 10 9E /lit e r yes yes no
'Two or more of the following: muscu lar rigidity; dystonic reaction; cogwhe el ing ; pa rkinson-
Ism .
2Two or mor e of the following: fluc tuating blood pr essure; ta chycardia; tachypn ea ; diaphor esis;
ur inary incontine nce.
3In the abse nce of one of th e three major crit eria, pro bable diagnosis is still permitt ed if th e
patient clearly me ets the two remaining major criteria , and displays one of th e minor crite ria.
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TABLE 3.
Application of Caroff's Diagnostic Criteria of NMS
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Case #1 Case # 2 Case # 3
Neuroleptic treatment within 7 days of on set (2-4
weeks for depot pr ep arations) yes yes yes
Hyperthermia ( > = 38°C) yes yes yes
Muscle rigidity yes no yes
Five of th e following
Alt ered mental status yes yes yes
Tachycardia yes no yes
Hyper/ hypotension yes no yes
T achypnea /Hypoxi a yes no no
Diaphor esis /Sia lorrhea yes no yes
Dysarthria/Dysphagia yes no ?
Tremor yes yes no
In con t inence no no no
CK eleva tion yes yes yes
Myog lobinuria no no no
Leukocyt osis yes yes no
Absen ce of othe r e tiologies yes no no
dysfunction, aspiration pn eumonia , a nd becam e incr easingly confus ed . Antibiot ic therapy was
initiated to treat th e pn eumonia.
At psychiatric consu ltat ion th e patient was diaphoreti c, with a n ora l tem perature of
38.9°C, pul se of 104/min, respirat ion of 321m in, a nd fluctua ting blood pressur e betw een
160 / 90 to 108/ 50 mmHg. Mental sta tus exa m ina tion reveal ed confus ion, disor ientat ion, and
a n inability to com munica te verbally. Neurological exa m ina tion dem on st ra ted marked extra -
pyr amidal signs, including incr ea sed muscle ton e, with diffuse trem or , cogwhee ling, and
lead-pipe rigidity in th e upper ext re m ities. Serum che m ist ries revealed a C K level of 1267
U/lit er, leukocytosis (15 .0 X 109 E/ liter), a nd normal elec t ro lytes . A tentative di agnosis of
NMS was made. All psychotropic med ications were discontinued , support ive thera py was
initiated, and oral bromocryptine 2.5 mg three times daily was initiated a long with supportive
th erapy.
Ov er th e following four days th e patient 's mental sta t us cleared , ext ra pyra mida l symp-
tom s resolved, and vit al signs stabilized (te m pe ra ture 36.6°C, pul se 72/min, respirat ion
12/min, and blood pr es sure 120/70 mmHg). Laboratory values normal ized , with a CK of 123
U/ lit er, and WBC of 7.70 X 109 E/lit er. Bromocriptine was dis continued , a nd following a full
course of a nt ibio tic th erapy for pn eumonia the pa ti ent was disch arged in improved condition.
CASE # 2
A 72 yea r old man with a pr eadmission di agnosis of chro n ic schizophreni a and men tal
ret ardation was hospitalized for evalua tion and treatment of wea kness , lethargy, and fever of
unknown ori gin . His past medi cal history was significa nt for parkinsoni sm, hyper ten sion,
em physe ma , with ch ronic bronchit is, a nd a hearing deficit. Past su rgica l hist ory includ ed a
tr ansurethral prost at ect omy, and cho lecys tectomy. Medi cation s on adm ission includ ed ver apa-
mil 240 mg d aily, fluph en azine 2.5 mg daily, ben ztrop ine I mg daily, and ora l ana lges ics.
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Admission findings included temperature of 40°C, blood pressure of 118/70 mmHg, pul se
96 / m in, and respiration 26/m in, a marked hearing deficit , an d m ild parkinsonism (increased
mu scle ton e and t rem or). Blood tests were not abl e for WBC of 34.5 X 109 E/ lit er, incr eased
liver enzymes (lac ta te deh ydrogen ase 27 1 U/liter, a lka line phosphatase 236 U /liter, ga m ma
glu tamyl t ransferase 307 U / lite r, asparta te am ino- transferase 102 U/lit er, a nd a lanine
ami notransfe rase 125 U / liter), and se rum C K of 4543 U/ lit e r (with negative MB ). Electrocar-
diogra m did not reveal any ischemic changes, a nd se pt ic work-u p (cer ebrospinal fluid , blood
and uri ne cu lt ures, and ches t X- ray) was unreveali ng.
Empiric a nt ibiotic th erap y for pr esu m ed hepatobil ia ry in fect ion was ini tiated. Over th e
following day, th e patient deferv esced (te m pe ra ture 36.6°C), with a marked drop in se ru m C K
( 1467 U / lite r) and WBC ( 17.4 X 109 E/ lite r) . However, a psychiat ric consulta t ion was
obtaine d to eva lua te for NMS. On mental status exam ina tion, th e pat ient was a lert , oriented,
but un abl e to com mu nica te effec tively because of his heari ng deficit. There was no evide nce of
ac ute beh avior al or psychological abno rma lity. In th e abse nce of acute psychotic sympt oms,
dis continuation of fluph en azine wa s recommended . Ov er th e subseq ue n t four days, th e pati ent
cont inue d to improve, and a t th e time of disch arge from th e hospit al , his se rum CK was 398
U / liter WBC was 7.5 X 109 E/lit er, and liver enzymes were close to norm al.
CASE # 3
A 35-yea r-old man with acq ui re d immunod eficien cy synd rom e (AIDS) dementia com plex
an d hypert en sion en te re d th e hospit al for eva lua tion a nd t rea tmen t of new-on set lethargy,
wea kness, a nd peripheral neu ropathy. Hi s past psychi atric history was significant for depres-
sion a nd one suicide atte m pt (med ica tio n overdose) . Med icat ions on admission included
flucon azole, acyclovi r, tri methoprim , a nd dap son e. General ph ysica l and neurological exa mi na -
tion did not reveal any sign ificant abnormalit ies . On mental status exa m ina t ion, he exhibite d
ma rk ed a nxie ty a nd ag ita t ion, with mild cognit ive deficit s (impaired memory and conce nt ra -
tion ), but otherwise he was free of psyc ho tic or dep ressive symptoms. Admission laboratori es
were remarka ble only for a se ru m C K of 634 U '/Iiter, WBC of 2.5 X 109 E/liter, a nd lact at e
d eh ydrogen ase of353 U/lite r.
Early in th e course of hospital izat ion , t he patient 's a nxie ty a nd agitation wors en ed, an d he
becam e ext re mely comba t ive a nd un coop erat ive with di agn ost ic procedu res. Haloperidol, up
to 5 mg d aily, was us ed for sedat ion, a nd afte r receiving a tot al of 30 mg over six days, his
ph ysical and mental cond ition det eri orat ed markedl y. T emperatu re increased to 38.0°C , with
fluctuat ion s in blood pr essure fro m 110/ 60 mmHg to 120 / 80 mmHg, and pulse rat e up to
140/min. The patient a lso d evelop ed lead -p ipe rigidity in th e ext re m it ies, hyperreflexia , and
diaphoresis. Organic workup of his sympto ms was non cont ributory, with negative blood , urine
a nd ce re bro spina l fluid studies. Chest X-ray was norm al, a nd head magn eti c resonance
im aging was remarkable onl y for mild a tro phic cha nges .
At psychiatric cons ulta t ion mental st atus exa m ina t ion revealed confusion, stu por, and
impai red speech. Rep eated che mist ries were rem arkabl e for a se ru m C K of 50 1 U / lit er a nd
WBC 4.2 X 109 E/lit er. The possibility of NM S was rai sed , and halop eridol was discontinu ed,
with mod est improvem ent in men tal sta tus, au to no m ic dysfun ct ion , and extra pyra m idal
sym pto ms ove r th e next three days. The pat ient became afebri le wit h a tem perature of36 .5°C ,
a le r t, a nd was able to follow verba l com mands. Two days la ter , t he pa tie nt was st art ed on
a m pho te r icin B for a presumed fungal infec tion of the ce nt ra l nervou s system, and a fte r five
days ph en othiazin e deri vatives were adde d to his regimen to manage th e gastroint estinal side
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effects of th e antifungal agent. Subsequently th e patient became febril e and stu porou s, his
motor and autonomic function deteriorated, a nd serum CK incr ea sed to 1161 U / lit er.
Follow-up psychiatric consulta t ion, once again, suggested th e possibil ity of NMS an d
re commended abrupt withdrawal of ph enothiazines . Despit e th e discontinuat ion of th e
neuroleptic ag ent , no significant improvem ent follow ed , and th e patient was transfer red to the
int en sive care unit and subsequently discharged to a n int ensive nursing ca re facil ity.
DISCUSSION
First described in the lit erature by Delay and Deniker ( 16), as a se rious
complication of treatment with neuroleptics, NMS is characte rized by hyperth er mia ,
parkinsonism, and eleva te d serum CK. However, retrospecti ve st udies have dem on-
strated that this syndrome is easily confused with other clinical problems in com pli-
cate d medical patients (17). Our cases illustrate th e difficulties of diagn osin g NMS in
patients with concom itan t medical illn ess.
Diagnosis of NMS in case # I was bas ed on con sid eration of mult iple factors. His
risks for dev eloping NMS included receiving intramuscul ar high pot en cy neurolept ic
(haloperidol) and increased doses of triftuperazine in th e sett ing of a pre-ex ist ing
brain pathology (m ental ret ardation) and other conc urre nt risk factors (see T abl e I).
Evaluation of his clinical presentation satisfied both Keck and Caroff's diagnost ic
criteria of NMS (se e Tables 2 and 3). Although fever could have been att r ibut ed to
th e pn eumonia, th e patient 's medical condit ion could not ex plain th e severe parkin-
sonism and autonomic instability. Marked resolution of th e symptoms following
abrupt withdrawal of neuroleptics, and institution of supportive th erap y a nd trea t-
ment with bromocriptine, furth er supported th e diagnosis of NM S. Fin ally, eleva ted
serum CK may have been secondary to bone fra cture, but th e dramatic drop in CK
level following dis continuation of haloperidol and trifluperazine a lso favored th e
diagnosis of NMS. It is of note that this patient presented with a history of iron
deficiency anemia, whi ch has been reported by som e investigators as a pot en tial risk
factor for NMS (18).
In contrast to patient # I, NMS was rul ed out in patient #2 following consider-
a tion of his symptoms, clinical course, and lack of th e signifi cant risk factors (see
T abl es 1-3) . The patient had a history of chronic schizophreni a and rriental retarda-
tion, but the absence of any recent change in th e dos e or rout e of ad min istrat ion of
fluphenazine made th e diagnosis of NMS less likely. The mild ext rapyra mida l
symptoms in this patient, although suggestive of NMS , may hav e been due to his
pr e-existing parkinsonism. Furthermore, th e course of thi s patient 's illn ess was not
typi cal for NMS. Recent studies hav e shown that th e mean duration ofNMS following
appropriate treatment is 6.8 days (19). Thus, th e rapid resolution of fever, leukocyto-
sis, and liver enzyme alterations were more likely due to a nt ibiotic th erap y for the
pr esumed biliary tract infection, rather the dis continuation of fluph en azi ne.
The presentation and clinical course of patient # 3 illu strates a d iagnost ic
dil emma. Despite this patient 's young ag e, his concurre n t br ain pathology (AIDS-
dementia com plex) put him at high risk for NMS when ex posed to high pot ency
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neuroleptics (6). Hi s clinical course is cons isten t with NMS by both Keck and Caroff's
di agn ostic cri teria (see T abl es 2 and 3) . Furt hermore, th e remission and relapse of
sym pto ms afte r withd rawal of haloperidol a nd ini tiation of ph enothiazine derivatives
resp ecti vely, also favor the di agnosis ofNMS . H owever , it is difficult to distinguish th e
neu rol eptic side effects fro m sym pto ms of AIDS-d ementia complex . Human immuno-
deficien cy viru s (H IV) in fection has been associa te d wi th subacute ence pha lit is a nd
asep tic meningi tis cha racte rized by men tal confus ion progressing to dementia, fever,
m et abolic abnormalit ies, fat igue, and movemen t disorder (20) . Therefore, th e
hyperthermia, mot or dysfuncti on , and al tered se nsorium in t his patient could be
a tt r ibu te d to HIV ence phalopa t hy, es pecia lly in the view of the overall progression of
th e sym ptoms eve n afte r th e final withdrawal of pheno thiazine derivatives.
These three cases illu strate the difficulties tha t clin icians face in acc ura te
identification of NMS in the me dica lly ill. Carefu l rev iew of the temporal relation-
ships of drug ad mi nist ra t ion a nd th e seq ue nce a nd nature of clinical manifestation s
as th e syndrome evolves, fac ilitate th e diagn osis. Even whe n diagnostic un certainty
ex ists, we propose th at in high-risk patients, neu rolept ic medications sh ould be
withhe ld , and non-neuroleptic tr eatment strategies be considered to cont ro l th e
resid ual behavior probl ems.
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